TruSpine Technologies PLC Update re Loan (6367Y)
May 09 2023 - 1:00AM
UK Regulatory
TIDMTSP
RNS Number : 6367Y
TruSpine Technologies PLC
09 May 2023
9 May 2023
TruSpine Technologies plc
("TruSpine" or the "Company")
Update re Loan
TruSpine Technologies Plc, the medical device company focused on
the spinal (vertebral) stabilisation market, announces an update to
the announcement released by the Company on 28 February 2023 in
relation to the Loan Agreement entered into by the Company.
The announcement of 28 February 2023 omitted to disclose a fixed
and floating charge over the Company's intellectual property to the
lender as security for the proceeds of which were received on 27
February 2023. A registration of charge was registered on Companies
House in relation to this matter on 28 April 2023.
Capitalised terms used in this announcement shall, unless
otherwise defined, have the same meanings as set out in the
Company's announcement of 28 February 2023.
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation, and the Directors of the Company
are responsible for the release of this announcement.
Enquiries:
TruSpine Technologies Plc Tel: +44 (0)20 7118 0852
Laurence Strauss, Chief Executive Officer
Cairn Financial Advisers LLP (AQSE Corporate Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
Oberon Capital (Joint Broker)
Tel: +44 (0)20 3179 5300
Mike Seabrook / Chris Crawford
Peterhouse Capital Limited (Joint Broker & Financial Adviser)
Tel: +44 (0)20 7469 0930
Lucy Williams / Duncan Vasey
Novus Communications (PR and IR) Tel: +44 (0)207 448 9839
Alan Green / Jacqueline Briscoe novuscomms@truspine.org
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXSSMFIIEDSEDI
(END) Dow Jones Newswires
May 09, 2023 02:00 ET (06:00 GMT)
TruSpine Technologies (AQSE:TSP)
Historical Stock Chart
From Nov 2024 to Dec 2024
TruSpine Technologies (AQSE:TSP)
Historical Stock Chart
From Dec 2023 to Dec 2024